Literature DB >> 30096291

Distinguishing neurocysticercosis epilepsy from epilepsy of unknown etiology using a minimal serum mass profiling platform.

Jay S Hanas1, James R Hocker1, Govindan Ramajayam2, Vasudevan Prabhakaran2, Vedantam Rajshekhar2, Anna Oommen2, Josephine J Manoj2, Michael P Anderson3, Douglas A Drevets4, Hélène Carabin5.   

Abstract

Neurocysticercosis is associated with epilepsy in pig-raising communities with poor sanitation. Current internationally recognized diagnostic guidelines for neurocysticercosis rely on brain imaging, a technology that is frequently not available or not accessible in areas endemic for neurocysticercosis. Minimally invasive and low-cost aids for diagnosing neurocysticercosis epilepsy could improve treatment of neurocysticercosis. The goal of this study was to test the extent to which patients with neurocysticercosis epilepsy, epilepsy of unknown etiology, idiopathic headaches and among different types of neurocysticercosis lesions could be distinguished from each other based on serum mass profiling. For this, we collected sera from patients with neurocysticercosis-associated epilepsy, epilepsy of unknown etiology, recovered neurocysticercosis, and idiopathic headaches then performed binary group comparisons among them using electrospray ionization mass spectrometry. A leave one [serum sample] out cross validation procedure was employed to analyze spectral data. Sera from neurocysticercosis patients was distinguished from epilepsy of unknown etiology patients with a p-value of 10-28. This distinction was lost when samples were randomized to either group (p-value = 0.22). Similarly, binary comparisons of patients with neurocysticercosis who has different types of lesions showed that different forms of this disease were also distinguishable from one another. These results suggest neurocysticercosis epilepsy can be distinguished from epilepsy of unknown etiology based on biomolecular differences in sera detected by mass profiling.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Electrospray mass spectrometry; Epilepsy; India; Neurocysticercosis; Serum

Mesh:

Year:  2018        PMID: 30096291      PMCID: PMC6171118          DOI: 10.1016/j.exppara.2018.07.015

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  34 in total

1.  Composition of the peptide fraction in human blood plasma: database of circulating human peptides.

Authors:  R Richter; P Schulz-Knappe; M Schrader; L Ständker; M Jürgens; H Tammen; W G Forssmann
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-04-16

2.  Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures.

Authors:  V Rajshekhar; M J Chandy
Journal:  Acta Neurol Scand       Date:  1997-08       Impact factor: 3.209

3.  Taenia solium: WHO endemicity map update.

Authors:  M Donadeu; M W Lightowlers; A S Fahrion; J Kessels; B Abela-Ridder
Journal:  Wkly Epidemiol Rec       Date:  2016-12-09

4.  Neurocysticercosis: an update.

Authors:  Christina M Coyle
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

5.  Inflammation and epilepsy.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

6.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Authors:  Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

Review 7.  Imaging findings in neurocysticercosis.

Authors:  Héctor H García; Oscar H Del Brutto
Journal:  Acta Trop       Date:  2003-06       Impact factor: 3.112

8.  Biomarker identification in human pancreatic cancer sera.

Authors:  Jay S Hanas; James R Hocker; John Y Cheung; Jason L Larabee; Megan R Lerner; Stan A Lightfoot; Daniel L Morgan; Kent D Denson; Kristi C Prejeant; Yuiry Gusev; Brenda J Smith; Rushie J Hanas; Russell G Postier; Daniel J Brackett
Journal:  Pancreas       Date:  2008-01       Impact factor: 3.327

Review 9.  Immunological and molecular diagnosis of cysticercosis.

Authors:  Silvia Rodriguez; Patricia Wilkins; Pierre Dorny
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

10.  Comparative Study of Paired Serum and Cerebrospinal Fluid Samples from Neurocysticercosis Patients for the Detection of Specific Antibody to Taenia solium Immunodiagnostic Antigen.

Authors:  Yasuhito Sako; Osvaldo M Takayanagui; Newton S Odashima; Akira Ito
Journal:  Trop Med Health       Date:  2015-05-22
View more
  2 in total

Review 1.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

2.  Distinguishing Alzheimer's Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis.

Authors:  Jay S Hanas; James R S Hocker; Christian A Vannarath; Megan R Lerner; Scott G Blair; Stan A Lightfoot; Rushie J Hanas; James R Couch; Linda A Hershey
Journal:  Brain Sci       Date:  2021-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.